Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
909.60 JPY | +0.85% | -1.52% | -7.65% |
Dec. 26 | Sekisui Chemical to Begin Mass Production of Perovskite Solar Cells | MT |
Dec. 26 | Sekisui Chem to begin mass production of perovskite solar cells in 2027 | RE |
Fiscal Period: March | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 2,262B | 2,426B | 2,496B | 2,548B | 2,322B | |||||
Total Revenues | 2,262B | 2,426B | 2,496B | 2,548B | 2,322B | |||||
Cost of Goods Sold, Total | 1,857B | 2,005B | 2,064B | 2,217B | 1,974B | |||||
Gross Profit | 405B | 421B | 432B | 331B | 348B | |||||
Selling General & Admin Expenses, Total | 330B | 317B | 325B | 340B | 349B | |||||
R&D Expenses | 23.85B | 20.97B | 21.71B | 17.01B | 19.69B | |||||
Other Operating Expenses | - | - | - | - | - | |||||
Other Operating Expenses, Total | 354B | 338B | 347B | 357B | 368B | |||||
Operating Income | 51.46B | 83.11B | 84.72B | -25.72B | -20.34B | |||||
Interest Expense, Total | -4.7B | -5.51B | -4.45B | -9.3B | -10.8B | |||||
Interest And Investment Income | 4.42B | 4.06B | 4.13B | 4.21B | 6.42B | |||||
Net Interest Expenses | -279M | -1.45B | -322M | -5.08B | -4.38B | |||||
Income (Loss) On Equity Invest. | -4.08B | -16.7B | 3.63B | -20.4B | 8.36B | |||||
Currency Exchange Gains (Loss) | 3.05B | 5.55B | 18.95B | 17.22B | 13.36B | |||||
Other Non Operating Income (Expenses) | 25M | -7.33B | 7.99B | 3.49B | -4.08B | |||||
EBT, Excl. Unusual Items | 50.17B | 63.18B | 115B | -30.49B | -7.08B | |||||
Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | -13.28B | -1.99B | 461M | 12.56B | 3.56B | |||||
Gain (Loss) On Sale Of Assets | 2.5B | 4.99B | 4.54B | 5.86B | -75M | |||||
Asset Writedown | -3.4B | -6.42B | -22.7B | -221B | -122B | |||||
Legal Settlements | - | - | -2.76B | - | - | |||||
Other Unusual Items | -3.66B | 6.69B | -4.69B | -6.42B | -11.63B | |||||
EBT, Incl. Unusual Items | 32.33B | 66.44B | 89.8B | -239B | -138B | |||||
Income Tax Expense | 17.77B | 14.22B | 16.04B | 22.61B | 12.52B | |||||
Earnings From Continuing Operations | 14.56B | 52.23B | 73.76B | -262B | -150B | |||||
Net Income to Company | 14.56B | 52.23B | 73.76B | -262B | -150B | |||||
Minority Interest | -831M | 1.04B | 234M | 814M | 104M | |||||
Net Income - (IS) | 13.73B | 53.26B | 73.99B | -261B | -150B | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 13.73B | 53.26B | 73.99B | -261B | -150B | |||||
Net Income to Common Excl. Extra Items | 13.73B | 53.26B | 73.99B | -261B | -150B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 22.47 | 87.2 | 121.14 | -407.31 | -230.99 | |||||
Basic EPS - Continuing Operations | 22.47 | 87.2 | 121.14 | -407.31 | -230.99 | |||||
Basic Weighted Average Shares Outstanding | 611M | 611M | 611M | 640M | 649M | |||||
Net EPS - Diluted | 22.47 | 87.2 | 121.14 | -407.31 | -230.99 | |||||
Diluted EPS - Continuing Operations | 22.47 | 87.2 | 121.14 | -407.31 | -230.99 | |||||
Diluted Weighted Average Shares Outstanding | 635M | 611M | 611M | 640M | 649M | |||||
Normalized Basic EPS | 49.98 | 66.34 | 118.02 | -28.48 | -6.66 | |||||
Normalized Diluted EPS | 48.07 | 66.34 | 118.02 | -28.48 | -6.66 | |||||
Dividend Per Share | 18 | 30 | 40 | - | - | |||||
Payout Ratio | 109.49 | 20.61 | 24.75 | -9.36 | -0.02 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 124B | 155B | 157B | 64.08B | 45.87B | |||||
EBITA | 51.46B | 83.11B | 84.72B | -25.72B | -20.34B | |||||
EBIT | 51.46B | 83.11B | 84.72B | -25.72B | -20.34B | |||||
Effective Tax Rate - (Ratio) | 54.97 | 21.39 | 17.87 | -9.46 | -9.1 | |||||
Total Current Taxes | - | - | - | - | - | |||||
Total Deferred Taxes | - | - | - | - | - | |||||
Normalized Net Income | 30.53B | 40.52B | 72.09B | -18.24B | -4.32B | |||||
Non-Cash Pension Expense | 32.79B | 10.03B | 9.17B | -2B | 1.88B | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 37.71B | 41.12B | 44.54B | 44.61B | 44.36B | |||||
Research And Development Expense From Footnotes | 101B | 86.79B | 86.29B | 78.71B | 73.02B |